Lucid Diagnostics Stock Performance
| LUCD Stock | USD 1.19 0.05 4.39% |
The company secures a Beta (Market Risk) of 0.48, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lucid Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Lucid Diagnostics is expected to be smaller as well. Lucid Diagnostics right now secures a risk of 3.42%. Please verify Lucid Diagnostics maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to decide if Lucid Diagnostics will be following its current price movements.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Lucid Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental indicators, Lucid Diagnostics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 18.9 M | |
| Total Cashflows From Investing Activities | -646 K | |
| Free Cash Flow | -44.8 M |
Lucid Diagnostics Relative Risk vs. Return Landscape
If you would invest 121.00 in Lucid Diagnostics on November 3, 2025 and sell it today you would lose (2.00) from holding Lucid Diagnostics or give up 1.65% of portfolio value over 90 days. Lucid Diagnostics is currently generating 0.0298% in daily expected returns and assumes 3.4153% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Lucid, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lucid Diagnostics Target Price Odds to finish over Current Price
The tendency of Lucid Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.19 | 90 days | 1.19 | about 13.85 |
Based on a normal probability distribution, the odds of Lucid Diagnostics to move above the current price in 90 days from now is about 13.85 (This Lucid Diagnostics probability density function shows the probability of Lucid Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Lucid Diagnostics has a beta of 0.48. This indicates as returns on the market go up, Lucid Diagnostics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Lucid Diagnostics will be expected to be much smaller as well. Additionally Lucid Diagnostics has an alpha of 0.0032, implying that it can generate a 0.003172 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Lucid Diagnostics Price Density |
| Price |
Predictive Modules for Lucid Diagnostics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lucid Diagnostics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lucid Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lucid Diagnostics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Lucid Diagnostics is not an exception. The market had few large corrections towards the Lucid Diagnostics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lucid Diagnostics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lucid Diagnostics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0 | |
β | Beta against Dow Jones | 0.48 | |
σ | Overall volatility | 0.06 | |
Ir | Information ratio | -0.0044 |
Lucid Diagnostics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lucid Diagnostics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lucid Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Lucid Diagnostics may become a speculative penny stock | |
| Lucid Diagnostics had very high historical volatility over the last 90 days | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.35 M. Net Loss for the year was (45.53 M) with loss before overhead, payroll, taxes, and interest of (2.56 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (44.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders |
Lucid Diagnostics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lucid Stock often depends not only on the future outlook of the current and potential Lucid Diagnostics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lucid Diagnostics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 50.5 M | |
| Cash And Short Term Investments | 22.4 M |
Lucid Diagnostics Fundamentals Growth
Lucid Stock prices reflect investors' perceptions of the future prospects and financial health of Lucid Diagnostics, and Lucid Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lucid Stock performance.
| Return On Equity | -3.31 | |||
| Return On Asset | -0.79 | |||
| Operating Margin | (9.71) % | |||
| Current Valuation | 180.73 M | |||
| Shares Outstanding | 131.1 M | |||
| Price To Book | 2.16 X | |||
| Price To Sales | 35.46 X | |||
| Revenue | 4.35 M | |||
| EBITDA | (44.34 M) | |||
| Cash And Equivalents | 34.46 M | |||
| Cash Per Share | 0.89 X | |||
| Total Debt | 21.25 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | (0.23) X | |||
| Cash Flow From Operations | (44.14 M) | |||
| Earnings Per Share | (0.77) X | |||
| Total Asset | 30.71 M | |||
| Retained Earnings | (203.77 M) | |||
About Lucid Diagnostics Performance
By analyzing Lucid Diagnostics' fundamental ratios, stakeholders can gain valuable insights into Lucid Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lucid Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lucid Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange.Things to note about Lucid Diagnostics performance evaluation
Checking the ongoing alerts about Lucid Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lucid Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lucid Diagnostics may become a speculative penny stock | |
| Lucid Diagnostics had very high historical volatility over the last 90 days | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.35 M. Net Loss for the year was (45.53 M) with loss before overhead, payroll, taxes, and interest of (2.56 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (44.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Lucid Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lucid Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Lucid Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lucid Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lucid Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lucid Diagnostics' stock. These opinions can provide insight into Lucid Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |